Health & Fitness
Wed, September 5, 2012
EWING, N.J.--([ BUSINESS WIRE ])--Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present at the Stifel Nicolaus 2012 Healthcare Conference on Thursday, September 6, 2012 at 8:35 am Eastern Time.
A live webcast of the presentation will be available via the aInvestor Relationsa page of the Antares website, [ www.antarespharma.com ]. A replay of the webcast will also be archived on Antaresa website for 90 days following the presentation.
About Antares Pharma
Antares Pharma focuses on self-injection pharmaceutical products and topical gel-based medicines. The Company's subcutaneous and intramuscular injection technology platforms include Vibexa" disposable pressure-assisted auto injectors, disposable multi-use pen injectors and Visiona" reusable needle-free injectors marketed as Tjet and Zomajet by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. In the injector area, Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin human growth hormone (hGH) and a partnership with Ferring that includes Zomacton hGH. In the gel-based area, the Company's FDA approved product is Gelnique 3%a" for the treatment of OAB (overactive bladder) marketed by Watson Pharmaceuticals, Inc. in the U.S. Antaresa portfolio includes Elestrin (estradiol gel) indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and marketed in the U.S. by Jazz Pharmaceuticals. Antares Pharma has two facilities in the U.S. The Parenteral Products Group located in Minneapolis, Minnesota directs the manufacturing and marketing of the Companyas reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted auto injector and pen injector systems. The Companyas corporate offices and Pharma Group are located in Ewing, New Jersey, where pharmaceutical products are developed utilizing both the Companyas transdermal systems and drug/device combination products.
